CD44 and cancer: Moreover, DHPMs modulate the CD44+/CD24− phenotype leading to a decrease in the CSC population in MDA-MB-231 cells, an important effect since CSC are resistant to many conventional cancer therapies and play a pivotal role in tumor initiation and maintenance.